---
title: "Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/600566.SH.md"
symbol: "600566.SH"
name: "Hubei Jumpcan Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
---

# Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SH)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.jumpcan.com](https://www.jumpcan.com) |

## Company Profile

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxifi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:10.000Z

**Overall: C (0.50)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -31.15% |  |
| Net Profit YoY | -40.64% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.81 |  |
| Dividend Ratio | 7.67% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25.04B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.14B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.84% | B |
| Profit Margin | 26.88% | A |
| Gross Margin | 77.77% | A |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -31.15% | E |
| Net Profit YoY | -40.64% | D |
| Total Assets YoY | -8.92% | E |
| Net Assets YoY | -1.68% | D |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 372.08% | C |
| OCF YoY | -31.15% | E |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.35 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 16.18% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Hubei Jumpcan Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.84%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "26.88%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.77%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-31.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-40.64%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.92%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.68%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "372.08%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-31.15%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "16.18%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.17 | 10/222 | 14.76 | 11.99 | 11.33 |
| PB | 1.81 | 61/222 | 1.81 | 1.75 | 1.66 |
| PS (TTM) | 4.08 | 98/222 | 3.97 | 3.51 | 3.33 |
| Dividend Yield | 7.67% | 3/222 | 8.06% | 7.71% | 4.82% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-09T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 1 | 100% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.18 |

## References

- [Company Overview](https://longbridge.com/en/quote/600566.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/600566.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/600566.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.